Global Oligonucleotide Therapeutics Market 2018-2022 | Increasing Incidence of Cancer to Boost Growth| Technavio

The global oligonucleotide therapeutics market is expected to post a
CAGR of close to 10% over the period 2018-2022, according to the latest
market research report by Technavio.

This press release features multimedia. View the full release here:

Technavio has published a new market research report on the global oligonucleotide therapeutics market from 2018-2022. (Graphic: Business Wire)

A key factor driving the growth of the market is the increasing
incidence of cancer and infectious diseases is leading to the demand for
novel diagnostics. To accurately detect cancer cells, diagnostic tests
primarily rely on antibody-antigen binding assays which may have a few
limitations such as the inability to detect minor antibodies.
Oligonucleotide therapeutics provide a new class of nucleic acid probes
known as aptamers which are better probes than monoclonal antibodies.
Thus, the rising prevalence of chronic and infectious diseases will lead
to an increase in demand for novel therapies, thus benefitting the
oligonucleotide therapeutics market

This market research report on the global
oligonucleotide therapeutics market 2018-2022 further provides
an analysis of the most important trends expected to impact the market
outlook during the forecast period. Technavio classifies an emerging
trend as a major factor that has the potential to significantly impact
the market and contribute to its growth or decline.

This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing

In this report, Technavio highlights the increase in M&A as one of the
key emerging trends in the global oligonucleotide therapeutics market:

Global oligonucleotide therapeutics market:
Increase in M&A

The increasing need to improve technical expertise in oligonucleotide
therapeutics has led to an increase in M&A. Players in the market are
engaging in partnerships to encourage the development of innovative
therapies to treat diseases with no treatment options. Increasing M&A
help companies to improve their technical expertise and product
portfolio in the oligonucleotide therapeutics market, thereby raising
the availability of products during the forecast period.

“Research companies and pharmaceutical companies make significant
investments in drug development to provide advanced treatment options
for patients. M&A help companies to pool their resources in terms of
technical skill, knowledge, prospective markets and funding to optimize
product development,” says a senior analyst at Technavio for
research on infectious and rare diseases.

Global oligonucleotide therapeutics market:
segmentation analysis

This market research report segments the global oligonucleotide
therapeutics market by application (neurological disorder, cancer, and
others), by technology (antisense/RNAi and others), and key regions (the
Americas, APAC, and EMEA).

Americas held the highest share of the global oligonucleotide
therapeutics market in 2017, accounting for a market share of around
40%, followed by EMEA and APAC respectively. The market share of EMEA is
expected to witness the maximum increase during the forecast period,
while the other two regions will see a decline in their market share
over the forecast period.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005441/en/